Literature DB >> 20887239

Age related macular degeneration and visual disability.

John B Christoforidis1, Nicola Tecce, Roberto Dell'Omo, Rodolfo Mastropasqua, Marco Verolino, Ciro Costagliola.   

Abstract

Age-related macular degeneration (AMD) is the leading cause of central blindness or low vision among the elderly in industrialized countries. AMD is caused by a combination of genetic and environmental factors. Among modifiable environmental risk factors, cigarette smoking has been associated with both the dry and wet forms of AMD and may increase the likelihood of worsening pre-existing AMD. Despite advances, the treatment of AMD has limitations and affected patients are often referred for low vision rehabilitation to help them cope with their remaining eyesight. The characteristic visual impairment for both forms of AMD is loss of central vision (central scotoma). This loss results in severe difficulties with reading that may be only partly compensated by magnifying glasses or screen-projection devices. The loss of central vision associated with the disease has a profound impact on patient quality of life. With progressive central visual loss, patients lose their ability to perform the more complex activities of daily living. Common vision aids include low vision filters, magnifiers, telescopes and electronic aids. Low vision rehabilitation (LVR) is a new subspecialty emerging from the traditional fields of ophthalmology, optometry, occupational therapy, and sociology, with an ever-increasing impact on the usual concepts of research, education, and services for visually impaired patients. Relatively few ophthalmologists practise LVR and fewer still routinely use prismatic image relocation (IR) in AMD patients. IR is a method of stabilizing oculomotor functions with the purpose of promoting better function of preferred retinal loci (PRLs). The aim of vision rehabilitation therapy consists in the achievement of techniques designed to improve PRL usage. The use of PRLs to compensate for diseased foveae has offered hope to these patients in regaining some function. However, in a recently published meta-analysis, prism spectacles were found to be unlikely to be of substantial benefit in people with age-related macular degeneration. Prescription filters are one of the most beneficial visual aids that people with macular degeneration. In principle, one aims both at reducing short-wavelength light to reduce glare and at identifying light with specific wavelengths (colours) preferred by the patient for viewing. In both instances, such interventions result in apparent improved contrast sensitivity and better visual acuity. Although specific tests are performed to determine the best colour, tint, lens material, and type of frame for the patient's need, no scientific protocol has been developed so far to assist in prescribing tinted or selective transmission lenses . Magnifying optical lenses are available in a wide range of dioptric powers and are made from materials that correct for weight (plastic), thickness (high index), spherical aberrations (aspherical), and variable light intensities (photochromatic). These lenses can be used as loose lenses, mounted on optical frames, or used with a wide variety of attachments. As the dioptric power of plus lenses increases, the viewing distance of the target decreases, hence their usefulness mainly for tasks requiring near resolution acuity, like reading. Magnification can also be achieved with the use of telescopic devices that are built of two or more plus and (or) minus (minifying) optical lenses. Normal resolution acuity levels can be achieved with these devices for all viewing distances. Therefore, all telescopic devices are useful only for stationary patient tasks that do not require mobility and orientation. Electronic magnification has the great advantage over plus lenses of producing an acuity reserve enabling reading skills for almost all levels of visual acuity. The additional benefit provided is preservation of binocularity, even at high levels of visual disparity between the two eyes. Vision rehabilitation can help patients to maximize their remaining vision and adapt to activities of daily living. The support of the patient's social network is critical to patient's well-being as patients adjust to being partially sighted.

Entities:  

Mesh:

Year:  2011        PMID: 20887239     DOI: 10.2174/138945011794182755

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  17 in total

1.  Severity of age-related macular degeneration at first presentation in Bhutan: a 3-year national study.

Authors:  Bhim B Rai; Michael G Morley; Paul S Bernstein; Ted Maddess
Journal:  BMC Ophthalmol       Date:  2022-07-09       Impact factor: 2.086

2.  Complement regulatory protein CD46 protects against choroidal neovascularization in mice.

Authors:  Valeriy Lyzogubov; Xiaobo Wu; Purushottam Jha; Ruslana Tytarenko; Michael Triebwasser; Grant Kolar; Paula Bertram; Puran S Bora; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2014-07-11       Impact factor: 4.307

3.  The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype.

Authors:  Valeriy V Lyzogubov; Puran S Bora; Xiaobo Wu; Leah E Horn; Ryan de Roque; Xeniya V Rudolf; John P Atkinson; Nalini S Bora
Journal:  Am J Pathol       Date:  2016-06-11       Impact factor: 4.307

4.  Evaluating Reading Performance in Different Preferred Retinal Loci in Persian-Speaking Patients with Age-Related Macular Degeneration.

Authors:  Abdollah Farzaneh; Abbas Riazi; Khalil Ghasemi Falavarjani; Asgar Doostdar; Mohammad Kamali; Ahad Sedaghat; Mehdi Khabazkhoob
Journal:  J Curr Ophthalmol       Date:  2021-03-26

5.  A prospective study on different methods for the treatment of choroidal neovascularization. The efficacy of verteporfin photodynamic therapy, intravitreal bevacizumab and transpupillary thermotherapy in patients with neovascular age-related macular degeneration.

Authors:  Michał S Nowak; Piotr Jurowski; Andrzej Grzybowski; Roman Goś; Mirosław Pastuszka; Andrzej Kapica; Janusz Śmigielski
Journal:  Med Sci Monit       Date:  2012-06

Review 6.  Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Authors:  Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2015-06-05

Review 7.  Vitamin A Update: Forms, Sources, Kinetics, Detection, Function, Deficiency, Therapeutic Use and Toxicity.

Authors:  Alejandro Carazo; Kateřina Macáková; Kateřina Matoušová; Lenka Kujovská Krčmová; Michele Protti; Přemysl Mladěnka
Journal:  Nutrients       Date:  2021-05-18       Impact factor: 5.717

8.  The Mind Cannot Go Blind: Effects of Central Vision Loss on Judging One's Crossing Time.

Authors:  Madeline Graber; Shirin E Hassan
Journal:  Optom Vis Sci       Date:  2020-06       Impact factor: 2.106

9.  Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo.

Authors:  Erika S Wittchen; Eiichi Nishimura; Manabu McCloskey; Haibo Wang; Lawrence A Quilliam; Magdalena Chrzanowska-Wodnicka; M Elizabeth Hartnett
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

Review 10.  The visual effects of intraocular colored filters.

Authors:  Billy R Hammond
Journal:  Scientifica (Cairo)       Date:  2012-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.